Beta Finch - Income & Dividends - EN

Beta Finch
  • 0.0 (0)
  • Investing

Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.

  1. 4d ago

    Philip Morris International Q2 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: INCOME (https://betafinch.com/groups/INCOME) ────────── Welcome to Beta Finch, your AI-powered earnings breakdown of the biggest names in the market. Here's the script for PMI's Q2 2026 call. --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Philip Morris International's second quarter 2026 results — and there's a lot going on here, including a CFO transition. But first, the standard stuff: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Right, and PMI gave us plenty to unpack. Let's start with the headline numbers, because they were strong. **ALEX:** Very strong. Organic net revenue growth of +8% for the quarter, operating income up +11%, and adjusted diluted EPS hit $2.20 — that's +14% currency-neutral, +15% in dollar terms. Quarterly net revenue crossed $11 billion for the first time ever. **JORDAN:** And this wasn't just a currency tailwind story either. Outgoing CFO Emmanuel Babeau flagged that about a third of the EPS beat came from a favorable tax-related currency effect tied to the Russian ruble, but two-thirds was real operating strength — better SG&A phasing and a surprisingly strong combustible business. **ALEX:** Let's talk about that smoke-free business first, because it's really the engine of this whole story. IQOS adjusted in-market sales volume grew +5% in the quarter — that sounds almost modest until you realize it includes two known headwinds: an excise tax hike in Japan and a flavor ban in Poland. **JORDAN:** Strip those out and IQOS growth was over 10% in Q2, north of 11% for the first half. That's the real underlying trend. IQOS also just cracked Kantar's list of top 100 most valuable global brands — pretty remarkable for a product that's only a decade old. **ALEX:** VEEV, their vapor brand, had an absolutely wild quarter — shipments up 55% in Q2, 72% for the half. Management says it's now the number one closed-pod brand in Europe and in global travel retail. **JORDAN:** Now let's get into the U.S., because this is where investors have been the most impatient. ZYN shipments grew 2% year-over-year to 2.9 billion pouches, and importantly, that's despite lapping an inventory tailwind from last year. Sequentially versus a rough Q1, U.S. net revenue was up 38%, gross profit up 46%. **ALEX:** The bigger story is the product lineup. They just launched ZYN Ultra — a lower-priced moist variant meant to close the gap with competitors — and they're bringing 1.5 and 8 milligram dry formats in Q3. Babeau was pretty clear-eyed that it's early days, just two weeks of data on Ultra, but the initial read and consumer feedback were encouraging. **JORDAN:** And there's a regulatory tailwind too — ZYN got Modified Risk Tobacco Product authorization on 20 SKUs, the only nicotine pouch product with that designation. That lets them actually market reduced-risk claims versus cigarettes, which is a real differentiator. **ALEX:** Here's the strategic pivot that stood out to me: management is choosing to step up U.S. investment hard in the second half — more marketing, a new brand campaign called "When It Clicks," expanded distribution — partly to build ZYN and partly to lay the groundwork for IQOS ILUMA's eventual U.S. launch, pending FDA action. **JORDAN:** Which is why, despite beating estimates two quarters in a row, PMI held its full-year guidance rather than raising it. An analyst from Goldman actually pushed on this directly, and Babeau basically confirmed: yes, the flat guidance reflects the decision to plow incremental profit back into U.S. investment rather than let it drop straight to the bottom line. **ALEX:** Let's touch on combustibles too, because cigarettes had a surprisingly strong quart This episode includes AI-generated content.

  2. 5d ago

    3M Q2 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: INCOME (https://betafinch.com/groups/INCOME), INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into 3M's second quarter 2026 results, and there's a lot to unpack here. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And Alex, this was genuinely a strong quarter for 3M. Organic growth of 5.4%, operating margin at 24.9% — that's their highest ever, by the way — EPS of $2.40, up 11% year-over-year, and free cash flow of $1.3 billion with 107% conversion. That's about as clean a beat as you'll see. ALEX: Right, and they didn't just beat expectations, they raised guidance across the board. Full-year organic growth guidance moved from 3% to greater than 3.5%. EPS guidance went from $8.50-$8.70 up to $8.80-$8.95. Free cash flow guidance ticked up $100 million to $4.7-$4.9 billion. JORDAN: What stood out to me is CEO Bill Brown was pretty emphatic this isn't a macro tailwind story. CFO Anurag Maheshwari basically said the same thing on the call — this is internal execution. Commercial excellence initiatives, better sales force effectiveness, cross-selling that's running 40% ahead quarter-over-quarter, and customer attrition improving about 200 basis points, mostly in their Safety & Industrial business. ALEX: And the innovation piece is a big part of the story too. They launched 92 new products in the quarter, up 44% year-over-year, putting them on pace for more than 350 new products this year. They're targeting over 1,000 new product launches by 2027, and development cycle time is down about 20%. JORDAN: The segment breakdown really tells the story. Safety & Industrial — that's SIBG — grew 8.2%, with double-digit growth across electrical markets, adhesives and tapes, abrasives, and industrial specialties. Transportation and Electronics grew 5.9%, helped by strength in semiconductors, aerospace, and data centers. But Consumer was the soft spot, down 2.1% for the quarter because of some retailer destocking in late June. ALEX: Now let's talk about the headline strategic news, because this is the part that got analysts excited. 3M announced a partnership with Microsoft — they're the first hyperscaler to deploy 3M's Expanded Beam Optical technology, or EBO, in Azure data centers. JORDAN: This is fascinating from a materials science angle. EBO is basically a more durable, dust-resistant fiber optic connector that Brown said can cut installation time in data centers by about 85%. They've got 100 patents already, 50 more pending. Revenue this year is only in the $40-50 million range, but Brown said it could scale 4x or 5x — or more — over the next few years as the broader market shifts from copper to optical. ALEX: And they're not trying to own the whole ecosystem either. They formed a 44-player multi-supplier agreement across hyperscalers, chip makers, and connector manufacturers. Brown was clear — they won't succeed as a sole provider, this is about industry-wide adoption. JORDAN: There was also the Madison Fire & Rescue deal — they closed on July 1st, folding it into their Scott SCBA business as a majority-owned joint venture, and picked up $700 million in cash in the process. That JV does about $800 million in revenue, growing high single digits with above-average margins. Classic example of reshaping the portfolio toward higher-growth, higher-margin businesses. ALEX: One thing I want to flag from the Q&A — China came up, and it's a much better story than a lot of people expected. Double-digit growth in the quarter, about 8% for the first half, and that's the seventh straight quarter of double-digit growth in India specifica This episode includes AI-generated content.

  3. Jul 16

    Abbott Laboratories Q2 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE), INCOME (https://betafinch.com/groups/INCOME) ────────── Welcome to Beta Finch, your AI-powered earnings breakdown. Here's the Abbott Labs (ABT) Q2 2026 script. --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Abbott Laboratories' second quarter 2026 results. Before we jump in, quick disclaimer — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Thanks, Alex. And there's a lot to like in this print. Let's start with the headline numbers. **ALEX:** Right, so Abbott posted sales growth of 4.8% for the quarter — that's an acceleration from the last two quarters — and adjusted EPS of $1.31, which beat both the midpoint of their guidance and consensus estimates. **JORDAN:** And here's the part investors really zeroed in on — Abbott didn't just reaffirm full-year sales guidance of 6.5% to 7.5%, they actually raised their EPS guidance range to $5.45 to $5.60. CEO Robert Ford was pretty clear that gross margin expansion is doing a lot of the heavy lifting there — margins came in at 58%, up 100 basis points year-over-year. **ALEX:** Let's talk segments, because there's a real story of divergence here. Medical devices grew 8.5%, led by electrophysiology — that's the heart rhythm and ablation business — which grew in the low teens. EPD, their emerging markets pharma division, grew 9%, powered by India, Latin America, and Southeast Asia. **JORDAN:** Diagnostics was mixed. Core lab was strong, U.S. up 7.5%. But rapid and molecular diagnostics — that's respiratory testing — declined 8% because it was just a weak flu and respiratory virus season. That's expected and temporary though, not a demand problem. **ALEX:** And then nutrition — this is the comeback story of the quarter. Sales came in ahead of expectations for the second straight quarter, up sequentially by $125 million. Ensure retail consumption in the U.S. is up double digits. **JORDAN:** Yeah, that's the price increases from late last year finally working through the system — volumes are responding well now that consumers have adjusted. Management is now framing nutrition as a sustainable 2-4% grower going forward. **ALEX:** Let's get into the strategic stuff, because there's a lot of pipeline news. Abbott completed enrollment in its coronary IVL trial, filed with the FDA for the Amulet 360 left atrial appendage device, and got a CE mark in Europe for Libre Duo — which is notable, it's the world's first dual glucose-ketone monitoring sensor, designed to help prevent diabetic ketoacidosis. **JORDAN:** The CGM story is worth sitting with for a second. Diabetes care crossed $2 billion in quarterly sales, growing 9.5%. Now, one analyst on the call kind of poked at that number as "only" 9.5%, and Ford pushed back — reasonably, I'd say. He pointed out there's 75 to 80 million people globally who could realistically use a CGM, and only 15 million currently do. Growth right now is basically waiting on reimbursement expansion, especially the big one: U.S. Type 2 non-insulin Medicare coverage, which could unlock roughly 10 million beneficiaries. Ford said that could happen this fall but wouldn't pin down an exact date. **ALEX:** They're also planning a fifth manufacturing facility for CGM sensors — a billion-dollar investment — because they expect to hit capacity limits at their current facility within a couple years. That's a pretty strong signal of how bullish they are on long-term demand. **JORDAN:** One theme that came up repeatedly in the Q&A was this investor worry about decelerating hospital procedure volumes — tied to ACA enrollment changes and Medicaid dynamics. This episode includes AI-generated content.

  4. Jul 15

    Johnson & Johnson Q2 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Johnson & Johnson's second quarter 2026 results, and Jordan, there's a lot to unpack here. JORDAN: There really is. But first, the fine print — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. ALEX: Right, so let's get into it. J&J posted $25.3 billion in quarterly sales, up 5.6% operationally. That doesn't sound huge until you realize they absorbed a 460 basis point headwind from STELARA losing patent protection to biosimilars. JORDAN: Yeah, strip out STELARA and the rest of the business grew double digits. That's the real story. Net earnings came in at $5.5 billion, diluted EPS of $2.27, and on an adjusted basis, EPS was $2.90, up nearly 5% year-over-year. And here's the kicker — they raised full-year guidance. Operational sales growth now expected at 6.5% to 7.1%, and adjusted EPS guidance moved up to $11.50-$11.65. ALEX: They're also closing in on a milestone — more than $100 billion in annual revenue for the first time in the company's 140-year history. JORDAN: Which is wild to say out loud. This is a company with 28 different products or platforms each doing over a billion dollars a year. That's not a one-hit-wonder portfolio, that's just breadth everywhere. ALEX: Let's talk oncology, because that's really where J&J flexed this quarter. DARZALEX, their multiple myeloma drug, did over $4 billion, up almost 18%. But the newer combo therapies are what caught my eye — CARVYKTI up 47.7%, TECVAYLI up 56%, TALVEY up 62.6%. JORDAN: Those growth rates on top of an already-dominant multiple myeloma franchise are pretty remarkable. And they're not resting — new data showed the TALVEY-DARZALEX combo keeping over 80% of patients progression-free at two years, with overall survival up to 89%. That's the kind of data that extends a franchise's life for years. ALEX: Then there's the newer launches — ICOTYDE in psoriasis, INLEXZO in bladder cancer, RYBREVANT in lung and now head-and-neck cancer. ICOTYDE in particular is getting a lot of attention. Over 11,000 patients started therapy, 6,000 unique prescribers, and more than half of commercial payers already covering it within 90 days. JORDAN: What's interesting is how they're positioning it alongside TREMFYA, which by the way had a monster quarter — 71% growth, its first $2 billion quarter. Instead of cannibalizing each other, management's framing ICOTYDE as the go-to first systemic treatment and TREMFYA as the first-choice biologic, especially for patients trending toward psoriatic arthritis. It's a two-pronged attack on the same disease area. ALEX: Now, MedTech was the softer spot this quarter — only 3.6% growth. Cardiovascular was the drag, mainly Abiomed's heart pump business. JORDAN: Right, and this is worth unpacking because it wasn't a demand problem. A neutral clinical trial out of the U.K. made physicians more cautious about patient selection for Impella devices, so usage slowed. Management was pretty direct about it — they called it a "behavioral" issue, not structural. They're leaning on their own much larger evidence base, over 40,000 patients studied versus the UK trial's 300, while they wait for their own PROTECT IV trial data, which won't read out until 2027. ALEX: Meanwhile, three of MedTech's four businesses — surgery, vision, and orthopedics — actually accelerated and beat expectations. So it's really one segment, heart recovery, dragging on an otherwise solid MedTech story. JORDAN: And there's real excitement building around the robotics pipeline — the OTTAVA surgical robot and MONARCH for urology are both awaiti This episode includes AI-generated content.

  5. Jul 9

    PepsiCo Q2 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME) ────────── Welcome to Beta Finch, your AI-powered earnings breakdown of the calls that move markets. Today we're digging into PepsiCo's Q2 2026 results. ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan, and today we're breaking down PepsiCo's second quarter 2026 earnings call. This one's got a real tale-of-two-businesses vibe — strong international, choppier North America. Before we dive in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Right, and there's a lot to unpack here, Alex. This wasn't a blowout quarter, but it also wasn't a disaster — it's more of a "here's exactly where the pressure points are" kind of call. ALEX: Let's start with the headline numbers. First-half revenue grew almost 7% company-wide, which is solid. Global volumes were up 3% in foods and 2% in beverages — CEO Ramon Laguarta called that the fastest volume growth since 2022. JORDAN: And on earnings, reported EPS grew 6% in the first half, constant currency EPS up 3%. They reaffirmed full-year guidance, though CFO Steve Schmitt flagged it might land toward the low end of their EPS range. ALEX: The story underneath those numbers, though, is really about a split business. International is on fire — set to cross $40 billion this year, growing 7% and accelerating. Meanwhile North America, especially the food business, PFNA, came in softer than expected. JORDAN: Yeah, PFNA volume was flat in the quarter. And that's notable because PepsiCo spent the first half of the year specifically investing in affordability — lowering prices, portion control packs — to get salty snacks volume growing again after a stretch of decline. ALEX: And it kind of worked, right? Laguarta made the point that the category went from negative volume to positive, and PepsiCo is actually gaining share within that. So directionally the strategy's working, just not as fast as hoped. JORDAN: Right, and he was pretty candid about why: gas prices. Rising fuel costs hit convenience and gas station channels hard — those impulse-purchase locations where price sensitivity shows up fast. People are pulling into the pump but not converting that traffic into snack and drink purchases the way they used to. ALEX: That convenience-and-gas weakness actually shows up directly in the numbers too. PBNA — the North America beverage business — saw operating margin down about 90 basis points. Steve Schmitt broke that into three pieces: about half tied to the Alani Nu commercial arrangement, then the soft convenience-and-gas channel, and product mix. JORDAN: What I found interesting was management resisting the idea of some big "reset" — a phrase one analyst used. Laguarta pushed back pretty firmly, saying they don't need one because of record productivity gains funding the growth investments. ALEX: There was also a nice tailwind mentioned — tariff refund claims from last year, expected to add about a full point of EPS growth for the full year. That's helping offset rising commodity costs, particularly some inflation expected in Europe and the Middle East in the back half. JORDAN: On the international side, it's honestly the highlight of the call. Laguarta did a world tour — Vietnam, Thailand, China, the Middle East, all more resilient than expected despite higher gas prices there too. Europe's getting a real boost from World Cup sponsorship activations. Latin America's a bit softer but still trending positive. ALEX: And Schmitt added that international operating margin actually grew a full point in the quarter — so it's not just top-line growth, it's profitable, efficient growth. JORDAN: One thing This episode includes AI-generated content.

  6. May 7

    McDonald's Q1 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME) ────────── # Beta Finch Podcast Script: McDonald's Q1 2026 Earnings **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and with me as always is Jordan. Today we're diving into McDonald's Q1 2026 results, and wow, there's a lot to unpack here. Jordan, before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN**: Thanks Alex, and yeah - McDonald's certainly delivered some interesting headlines this quarter. On the surface, the numbers look pretty solid - global comparable sales up 3.8%, system-wide sales growing 6% in constant currency. But when you dig deeper, there are some real challenges brewing beneath those golden arches. **ALEX**: Absolutely. Let's start with the good news. The U.S. business showed resilience with 3.9% comparable sales growth, and they're gaining market share in nearly all their top 10 markets globally. That's impressive in this environment. But Jordan, what really caught my attention was CEO Chris Kempczinski's emphasis on their "3 for 3" strategy - value, marketing, and menu innovation. **JORDAN**: Right, and the value piece is particularly crucial here. They've completely revamped their McValue platform with unanimous franchisee support - that's key. We're talking about items under $3 and a new $4 breakfast meal deal. Kempczinski was pretty emphatic about this, saying "McDonald's is not going to get beat on value and affordability." **ALEX**: That's a bold statement, but they're backing it up with action. What's interesting is they're applying lessons from international markets back to the U.S. Most of their major international markets already had this dual approach - both everyday affordable items and meal bundles. France was apparently the exception, which might explain some of their struggles there. **JORDAN**: Speaking of struggles, let's talk about the elephant in the room - those U.S. company-operated store margins. CFO Ian Borden was brutally honest, calling them "not acceptable." That's pretty remarkable transparency from a major corporation. **ALEX**: It really is. And when you connect the dots, this ties into a bigger strategic question about McDonald's ownership structure. They're essentially saying some of their franchisees are running restaurants better than McDonald's corporate is running their own locations. That's... not ideal. **JORDAN**: Exactly. And it sounds like they're seriously considering refranchising more company-operated stores. Kempczinski said they're "always looking to put restaurants in the hands of the best operator," which is diplomatic corporate-speak for "we might be selling these to franchisees who can run them better." **ALEX**: Let's shift to international markets for a moment. The UK really stood out as a success story - they're on their third consecutive quarter of market share gains with mid-to-high single-digit comp growth. Jordan, what's working there? **JORDAN**: It's that same formula - they introduced something called "Meal Deal Plus" for £5.59, which gives customers more flexibility. Plus they're executing well on marketing campaigns like the "Friends" TV show promotion. Australia's another bright spot using similar tactics. But then you have France struggling, which shows this isn't automatic - you have to execute consistently. **ALEX**: And speaking of execution, they're rolling out their new beverage platform globally. Yesterday, all U.S. restaurants started offering refreshers and crafted sodas under the McCafe brand, with Red Bull-infused energy drinks coming later this year. **JORDAN**: That timing on Red Bull is interesti This episode includes AI-generated content.

  7. May 2

    Colgate-Palmolive Q1 2026 Earnings Analysis

    **BETA FINCH PODCAST SCRIPT** **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the latest quarterly results and what they mean for investors. I'm Alex. **JORDAN**: And I'm Jordan. Today we're breaking down Colgate-Palmolive's Q1 2026 earnings call, and there's quite a bit to unpack here. **ALEX**: Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN**: Absolutely. Now, Alex, Colgate had an interesting quarter - some really strong performance in certain areas, but they're also dealing with significant headwinds. Where do you want to start? **ALEX**: Let's kick off with the headline numbers. Colgate delivered what CEO Noel Wallace called "strong top and bottom line growth" with organic sales growth actually accelerating from Q4. They saw growth in both volume and pricing across all four categories and four of five divisions, which is pretty impressive breadth. **JORDAN**: That's right, and what really caught my attention was the geographic mix. Emerging markets were the star of the show, particularly Asia Pacific. Wallace mentioned that these are regions where Colgate's global brands have higher market shares and greater scale advantages, so they're doubling down on investments there. **ALEX**: Speaking of investments, they're maintaining their focus on brand equity and advertising spending, which is notable given the cost pressures they're facing. But Jordan, let's talk about the elephant in the room - that $300 million increase in expected raw material and logistics costs. **JORDAN**: Yeah, this is where things get interesting from a margins perspective. They had to revise their gross margin outlook downward because of these cost pressures. CFO Stanley Sutula broke it down - about two-thirds of that $300 million hit is from raw materials, one-third from logistics. The big culprits? Oil byproducts like resins and petrochemicals, with spending in those areas expected to be up more than 20% year-over-year. **ALEX**: And they're assuming crude oil at around $110 for their planning purposes. But here's what I found encouraging - despite these headwinds, they reaffirmed their full-year guidance for both top and bottom line growth. How are they managing to do that? **JORDAN**: It comes down to what Wallace calls their "flexible P&L model." They're offsetting these cost pressures through several levers: revenue growth management, or RGM, productivity initiatives, and they just announced an acceleration of their Strategic Growth and Productivity Program - or SGPP. **ALEX**: Let's dig into that SGPP announcement because it's pretty significant. They're now targeting $200 million to $300 million in annualized savings, with most of those savings hitting in 2027 and 2028. Wallace emphasized this isn't an extension of the program - it's still completing by end of 2028 - but they've identified additional opportunities. **JORDAN**: Right, and Sutula explained that the strong execution from their teams allowed them to reach the high end of their initial targets, plus they found new ways to simplify operations and enhance efficiency. I like that they're being proactive about organizational structure and reducing complexity. **ALEX**: Now, the regional performance was really telling. Asia Pacific was a standout, with improvements in both China through their Hawley & Hazel business and strong performance in India. Wallace mentioned they're not "completely out of the woods" in China yet, but the interventions they've made - accelerated innovation, better omnichannel execution - are starting to pay off. **JORDAN**: Latin America also had another strong volume quarter with mid-single-digit growth. Wallace was particularly enthusiast This episode includes AI-generated content.

  8. Apr 30

    Altria Q1 2026 Earnings Analysis

    **BETA FINCH PODCAST SCRIPT** --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear, actionable insights. I'm Alex. **JORDAN:** And I'm Jordan. Today we're diving into Altria Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including a CEO transition and some fascinating market dynamics in both cigarettes and nicotine pouches. **ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Absolutely. Now, let's talk numbers first. Altria delivered a solid start to 2026 with adjusted diluted EPS growing 7.3% in Q1. They're maintaining their full-year guidance of $5.56 to $5.72 per share, which represents 2.5% to 5.5% growth. **ALEX:** That's a strong performance, but what really caught my attention was the underlying story about consumer behavior. Jordan, can you break down what's happening in the cigarette market? **JORDAN:** Sure thing. So there are two major trends colliding here. First, we're seeing moderation in the e-vapor category - particularly those illicit flavored disposable products that have been stealing cigarette smokers for years. Federal and state enforcement is finally having an impact, and it looks like the category may have hit a saturation point. **ALEX:** Which is helping cigarette volumes, right? They declined only 4% when adjusted for trade inventory movements, compared to much steeper declines we've seen in recent years. **JORDAN:** Exactly. But here's the fascinating part - all of this volume improvement is happening in the discount segment, not premium. Consumers are under serious economic pressure. Gas prices spiked, inflation is still biting, and people are trading down to cheaper brands. **ALEX:** And Altria is capturing that trade-down with their Basic brand. The numbers here are pretty impressive - Basic grew 2.4 share points year-over-year in the discount segment. Meanwhile, Marlboro actually lost 1.4 share points overall but gained in the premium segment specifically. **JORDAN:** That's the beauty of their portfolio strategy. They're essentially playing both ends of the market. When premium smokers stay loyal, Marlboro captures them. When economic pressure forces people to trade down, Basic is there waiting. **ALEX:** Now let's talk about the growth story - oral nicotine pouches. This category is absolutely exploding. Jordan, what's happening with their on! brand? **JORDAN:** The oral nicotine pouch segment now represents 58% of the total oral tobacco category - that's remarkable growth. Altria's on! portfolio shipped nearly 18% more volume, hitting over 46 million cans in Q1. They launched on! PLUS nationwide in March, and it's already in about 100,000 stores. **ALEX:** What makes on! PLUS special? **JORDAN:** Two things: it's the first and only product authorized under the FDA's pilot program for nicotine pouches, which should give them a regulatory advantage. And they're marketing it as "the softest pouch on the planet" using their proprietary NICOSILK technology. They're really trying to differentiate on the user experience. **ALEX:** Speaking of the FDA, there was interesting commentary about the regulatory environment. CEO William Gifford - and by the way, this was his final earnings call - was pushing hard for the FDA to streamline authorizations for e-vapor products. **JORDAN:** Right, and his logic makes sense. The e-vapor category is still about 70% illicit products. Gifford argued that faster authorizations combined with sustained enforcement could create a compliant marketplace where authorized manufacturers can serve adult consumers with quality products. **ALEX:** Let's talk about that CEO transition. Gifford is stepping d This episode includes AI-generated content.

See All (21)

About

Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.

Information